ArticleThe journal of headache and pain2022

Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.

Stephanie J Nahas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.